Ministry of Investment shared a post by Saudi Food and Drug Authority, adding:
“Anktiva, manufactured by ImmunityBio, has been approved by the Saudi_FDA. It is used to treat adults with bladder and lung cancer, the first globally approved therapy to act as a superagonist of interleukin-15 receptors.”
Quoting Saudi Food and Drug Authority’s post:
“A major step forward for treatment options in Saudi Arabia! SFDA has approved Anktiva for adult bladder cancer and lung cancer patients—marking approval for the world’s first IL-15 receptor superagonist.”
Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, also shared this post, adding:
“Forward thinking by a very sophisticated agency for the good of their nation and their citizens. Thank you on behalf of patients with cancer.”
Saudi FDA Approves Anktiva for Bladder and Lung Cancer
